Alex Zinoviev
Director - Messenger Ribonucleic Acid Platform Eli Lilly
Alex Zinoviev is currently leading the mRNA Platform at Eli Lilly, supporting all mRNA therapeutics programs and exploring cutting edge mRNA technology through collaboration with early stage biotech companies. Prior to Lilly, Alex worked at GreenLight Biosciences, where she was leading the RNA Technology team, developing a HT mRNA vaccine optimization platform and researching improvements in mRNA technology. Prior to that, Alex worked at Alltrna, where she was part of an early team building a platform for exploring tRNA technology as a novel therapeutic modality. Alex is an mRNA molecular biologist by training. In her PhD and postdoc she focused on molecular mechanisms of protein translation and cellular mRNA quality control.
Seminars
- What are the future opportunities, promising targets and applications on the horizon for mRNA to achieve commercial success?
- How are recent mRNA and LNP platform acquisitions fueling next generation innovations from science to strategy?
- Linear, circular, self-amplifying, trans-amplifying RNA – Which modality offers the most efficiency?
- With clinical trials moving towards the far East and Australia, what opportunities does this open for the mRNA industry to progress faster to clinical validation?
